At Esperion, we partner with companies that have proven expertise and passion for evolving scientific progress while addressing unmet patient needs in the cardiometabolic arena. Our established medicines offer new, innovative options for patients struggling with their LDL-C. We believe partnering with strong commercial organizations around the world is the best way to enable broad access to our medicines globally.
Partnering opportunities
Esperion is interested in evaluating late-stage through recently approved cardiometabolic assets that complement our current portfolio and leverage our established cardiovascular expertise and commercial capabilities. We are particularly focused on differentiated opportunities that address meaningful unmet patient needs and offer a clear path to near-term value creation and sustainable growth.
Next Generation ACLY Inhibitors
Esperion continues to build on its success with bempedoic acid by developing a series of novel Next Generation ATP-citrate lyase inhibitors (ACLYi). Our leading-edge approach to drug discovery integrates recent insights into the structure-function of ACLY, and its newly discovered role as a pathway nexus linking metabolism, immunity, inflammation and fibrosis. Our Next Generation drug discovery program has led to the development of highly potent, specific, and differentiated allosteric inhibitors optimized to address a variety of liver and kidney diseases.
We are seeking to accelerate some of these parallel programs with strategic partnerships.
There is significant opportunity, with the right partner, to discover and develop next gen ACLY inhibitor(s) that are optimized to beneficially modify multiple distinct diseases.
ENBUMYST™ (bumetanide nasal spray)
Esperion is evaluating strategic partnerships to support the development and commercialization of ENBUMYST outside the United States. We are interested in partners with regulatory, market access, and commercial capabilities, as well as clinical collaboration opportunities that can strengthen the evidence base and support broader patient access.
Established Partnerships
Our established partnerships to commercialize bempedoic acid and its combination with ezetimibe in Europe and Japan represent our largest agreements.
We have partnered with Daiichi Sankyo Europe to commercialize our two marketed products in the European Economic Area, UK, Turkey and Switzerland. Nilemdo® (bempedoic acid) Tablet and Nustendi® (bempedoic acid and ezetimibe) Tablet have launched in Germany, Switzerland, Austria, Belgium, Luxemburg, Netherlands, Spain, Italy, Slovakia, and Czech Republic with continued launches planned throughout the European Union.
In April 2021, we further expanded our partnership with Daiichi Sankyo, granting Daiichi Sankyo exclusive commercialization rights to bempedoic acid and the bempedoic acid & ezetimibe combination tablet in S. Korea, Taiwan, Hong Kong (products launched in September 2023), Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar. The terms allow for potential expansion across geographies in the Middle East and Latin America.
In Japan, have partnered with Otsuka Pharmaceutical Company to continue to develop and commercialize bempedoic acid and its combination with ezetimibe. The total value of the agreement is $600 million including milestones and development costs, and Otsuka will pay Esperion a significant royalty on all net sales. Otsuka will manage all ongoing development, regulatory approvals, and commercialization activities in Japan. Otuska plans to file for approval in 2024 with anticipated NHI pricing in 2025.
In December 2024, Esperion entered into an exclusive license, distribution, and supply agreement with Neopharm to commercialize bempedoic acid and its combination with ezetimibe in Israel and surrounding territories.
In March 2025, Esperion partnered with Seqirus Pty Ltd to commercialize its products in Australia and New Zealand.
In May 2025, we entered into a license and collaboration agreement with HLS Therapeutics Inc. to commercialize bempedoic acid and its combination with ezetimibe in Canada. Under the agreement, HLS is responsible for regulatory approval, reimbursement, and commercialization activities, and Esperion is eligible to receive milestones and tiered royalties on net sales.
In 2026, HLS Therapeutics announced the approval of Nilemdo® (bempedoic acid) in Canada, marking a key regulatory milestone for the partnership and advancing commercialization efforts in the Canadian market.
Reach out to our business development team to learn more about current partnership opportunities with Esperion.